We spoke with Dr. Priya Kumthekar and Dr. Alexander Stegh about their nucleic acid-based therapeutic development that targets glioblastoma.
Central Nervous System Cancer Targets
Researchers have now mapped genetic changes that help drive glioblastoma and are hoping this will lay the foundation for targeted treatment of the disease.
Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.
In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).
Many childhood brain tumors harbor potentially targetable gene mutations, according to a prospective single-institution study of more than 200 tumor samples, researchers reported in the journal Neuro-Oncology.
Researchers are reporting in the journal Cancer Research that they have identified a biomarker enzyme associated with aggressive glioma brain tumors. In addition, they have demonstrated potent efficacy in a mouse model of glioma for a small molecule inhibitor they recently developed.
A new study is suggesting that radiomic features subjected to machine learning algorithms may be able to identify imaging signatures that defined a subset of patients with recurrent glioblastoma who may gain the most benefit from antiangiogenic therapy.
A new study reveals clues on how brain tumors develop and spread, and this new information may provide valuable insight into diagnosis and treatment.
Researchers at the University of Pittsburgh have developed a sequencing test to analyze a broad spectrum of genetic alterations in central nervous system (CNS) tumors.
Dr. Marachelian and her team have demonstrated that there is a new treatment that is equivalent to a product that has been manufactured for commercial use and should be made available to patients outside of clinical trials.